Download PDF
Thromb Haemost 1985; 54(02): 442-444
DOI: 10.1055/s-0038-1657868
Original Article
Schattauer GmbH Stuttgart

Effect of Ciprofibrate on Platelet Aggregation and Fibrinolysis in Patients with Hypercholesterolaemia

Iain A Simpson
The University Department of Medical Cardiology and Department of Haematology, Royal Infirmary, Glasgow, UK
,
A Ross Lorimer
The University Department of Medical Cardiology and Department of Haematology, Royal Infirmary, Glasgow, UK
,
Isobel D Walker
The University Department of Medical Cardiology and Department of Haematology, Royal Infirmary, Glasgow, UK
,
John F Davidson
The University Department of Medical Cardiology and Department of Haematology, Royal Infirmary, Glasgow, UK
› Author Affiliations
Further Information

Publication History

Received 20 November 1984

Accepted 08 May 1985

Publication Date:
18 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The fibrinolytic and platelet effects of Ciprofibrate, a new lipid lowering drug, were studied in 7 patients with hypercholesterolaemia over a 12 week period. A significant reduction in plasma fibrinogen was noted and a lesser increase in fibrinolytic activity. However, no change in platelet aggregation was noted. As expected Ciprofibrate produced a significant hypolipidaemic effect in these patients.

We have described effects of Ciprofibrate which may have potential benefits in this high risk patient group.

Keywords

Ciprofibrate - Hypolipidaemic agent - Fibrinolytic activity - Fibrinogen - Hypercholesterolaemia
 

  • References

  • 1 Arnold A, McAuliff JP, Powers LG, Phillips DK, Beyler AL. The results of animal studies with Ciprofibrate, a new orally effective hypolipidaemic drug. Atherosclerosis 1979; 32: 155-163
    CrossrefPubMedGoogle Scholar
  • 2 Illingworth DR, Olsen GD, Cook SF, Sexton GJ, Wendel HA. Ciprofibrate in the Therapy of Type II Hypercholesterolaemia. A double-blind trial. Atherosclerosis 1982; 44: 211-221
    CrossrefPubMedGoogle Scholar
  • 3 Calvert GD, Blight L, Franklin J, Oliver J, Wise P, Gallus AS. The effect of Clofibrate on plasma glucose, lipoproteins, fibrinogen and other biochemical and haematological variables in patients with maturity onset diabetes mellitus. Eur J Clin Pharmacol 1980; 17: 355-362
    CrossrefPubMedGoogle Scholar
  • 4 Chakrabarti R, Fearnley GR. Effect of Clofibrate on fibrinolysis, platelet stickiness, plasma fibrinogen and serum cholesterol. Lancet 1968; 2: 1007-1009
    PubMedGoogle Scholar
  • 5 Cotton RC, Wade EG, Spiller GW. The effect of Atromid on plasma fibrinogen and heparin resistance. J Atheroscler Res 1963; 3: 648-652
    CrossrefPubMedGoogle Scholar
  • 6 Lipid Research Clinic Programme. Manual of Laboratory Operations. DHEW Publication No 1975 (NIH). 75-268
    PubMedGoogle Scholar
  • 7 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (eds) Vol 2 57-65 Raven Press; New York: -1976
    Google Scholar
  • 8 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 9 Friberger P, Knos M. Plasminogen assay in human plasma. In: Chromogenic Peptide Substrates (Chemistry and Clinical Usage). Scully MF, Kakkar VV. (eds) 128-140 Churchill Livingstone, Edinburgh: 1979
    Google Scholar
  • 10 Davignon J, Gascon B, Brossard D, Quidoz S, Leboeuf N, Le Lorier J. In: Lipoproteins and Coronary Atherosclerosis. Noseda G, Frogiacomo C, Fumagalli R, Paoletti R. (eds) 213-221 Elsevier Biomedical Press B. V.; Amsterdam: 1982
  • 11 Olsson AG, Oro L. Dose response study of the effect of Ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 1982; 42: 229-243
    CrossrefPubMedGoogle Scholar
  • 12 Lowe GDO, Drummond MM, Third JLHC, Bremner WF, Forbes CD, Prentice CRM, Lawrie TDV. Increased plasma fibrinogen and platelet aggregates in type II hyperlipoproteinaemia. Thromb Haemostas 1980; 42: 1503-1507
    PubMedGoogle Scholar
  • 13 McDonald L, Edgill M. Coagulability of the blood in ischaemic heart disease. Lancet 1975; 2: 457-463
    PubMedGoogle Scholar
  • 14 Baker IA, Eastham R, Elwood PC, Etherington M, O'Brien JR, Sweetnam PM. Haemostatic factors associated with ischaemic heart disease in men aged 45 to 64 years. The Speedwell Study. Br Heart J 1982; 47: 490-494
    CrossrefPubMedGoogle Scholar
  • 15 Meade TW, North WR, Chakrabarti R, Haines AP, North WRS, Stirling Yvonne, Thomson SG, Brozovic M. Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet 1980; 1: 1050-1054
    PubMedGoogle Scholar
  • 16 Research Committee of the Scottish Society of Physicians. Ischaemic Heart Disease: A secondary prevention trial using Clofibrate. Br Med J 1971; 4: 775-784
    CrossrefPubMedGoogle Scholar
  • 17 Physicians of the Newcastle upon Tyne Region. Trial of Clofibrate in the treatment of ischaemic heart disease. Br Med J 1971; 4: 767-774
    CrossrefPubMedGoogle Scholar
  • 18 Coronary Drug Project Research Group. JAMA. 1975; 231: 360-381
    PubMedGoogle Scholar
  • 19 Verheijen JH, Rijken DC, Chang GTG, Preston F, Kluft C. Decreased levels of rapid tissue-type plasminogen activator inhibitor by oral administration of Stanozalol. In: Progress in Fibrinolysis VII. Davidson JF, Donati MB, Coccheri SF. (eds) Churchill Livingstone, Edinburgh: 1985
    Google Scholar
  • 20 Whitaker KB, Costa D, Moss DW. Selective effects of Clofibrate on alkaline phosphatase coenzymes in serum. Clin Chim Acta 1979; 94: 191-196
    CrossrefPubMedGoogle Scholar
  • 21 Panchenko LF, Popova SV, Antonenkov VD. Inducing effect of Clofibrate on alkaline phosphatase and histidine ghyoxylate amino-transferase in rat liver. Experientia 1982; 38: 433-434
    CrossrefPubMedGoogle Scholar